Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Revel RX vs SnagRx

By GLP-1 ScorecardUpdated

Revel RXFactor scores not reassessed.
Site position #48

Higher score

SnagRx
Site position #339

Lower score

Score comparison

Revel RX has the higher recorded score — 77.3/100 to 57.9/100.

Revel RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Revel Rx advertises the same monthly price across doses and no separate membership fee. Its refund policy still refers to canceling a subscription.

Before you choose

Before comparing the headline prices, the Revel RX review and the SnagRx review set out the plan length, renewal date and extra fees behind each semaglutide figure in the table below, and the semaglutide cost page compares published rates across the field. A lower starting price can still mean a larger bill once a longer commitment or a separate membership is added.

If neither one fits, Revel RX vs Sunlight.com and RxPros vs SnagRx compare each of them with another graded program, and the list of alternatives to Revel RX ranks the programs closest to Revel RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueRevel RX +60
96
36
Dose & formulationRevel RX +8
72
64
Clinical oversightRevel RX +8
84
76
Labs & monitoringEven
53
53
FulfillmentRevel RX +10
81
71
Contract termsEven
55
55
Revel RX · top barSnagRx · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricRevel RXSnagRx
WeighScore77.3/10057.9/100
GradeC+C
Site position#48#339
Semaglutide$89/mo (advertised all doses, compounded)$99/mo (one-month compounded plan)
Tirzepatide$155/mo (advertised all doses, compounded)$149/mo (one-month compounded plan)
CoverageCoverage not publishedFAQ excludes Louisiana; confirm state eligibility
Brand-name accessNot confirmedNot confirmed
Oral / sublingualNot confirmedNot confirmed
Revel RX

Site position #48 · C+

Factor scores not reassessed.

Strengths

  • Publishes prices for both compounded medications
  • Advertises clinician review and included shipping
  • Provides written instructions for canceling before shipment

What to consider

  • The refund policy treats charged orders already handed to the carrier as final
  • No dispensing pharmacy assignment or state eligibility was verified for an individual order
SnagRx

Site position #339 · C

Strengths

  • One-month compounded injection plans advertised at $99 semaglutide / $149 tirzepatide
  • Three-, six- and twelve-month prepaid options with published totals
  • Terms name four possible pharmacy partners; individual assignment needs confirmation
  • Product pages advertise evaluation, medication, coaching, messaging and shipping

What to consider

  • Lowest $69/$119 monthly equivalents require $828/$1,428 twelve-month prepayments
  • Final pharmacy-related charges may vary despite flat-dose marketing
  • Refund policy makes payments final immediately; medical rejection refunds may deduct used services
  • Cancellation cutoffs differ: five days before the prescription period ends versus 72 hours before billing
  • Homepage state restrictions conflict with broader terms; confirm eligibility

Featured provider

SnagRx

SnagRx scores 57.9/100 (C). SnagRx lists one-month compounded injection plans at $99/$149, with prepaid discounts and refund rules to resolve before paying.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard